Floatz logo

AZD1775

CNS 2c

National Cancer Institute (NCI)Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the CNS 2c cohort.

Asset / SponsorPhaseRating
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
ENCENICLINE
FORUM Pharmaceuticals Inc
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

AZD1775 is also rated in:

refractory malignant neoplasmDormant
B
Indicative ·
62 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
60 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →